The FASEB Journal • Research Communication
A single-molecule force spectroscopy nanosensor for
the identification of new antibiotics and antimalarials
Xavier Sisquella,* Karel de Pourcq,† Javier Alguacil,‡ Jordi Robles,‡ Fausto Sanz,§
Dario Anselmetti,# Santiago Imperial,†,储 and Xavier Fernàndez-Busquets储,**,1
*Nanotechnology Platform, Barcelona Science Park, Barcelona, Spain; †Department of Biochemistry
and Molecular Biology, ‡Department of Organic Chemistry, §Department of Physical Chemistry, and
储
Biomolecular Interactions Team, Nanoscience and Nanotechnology Institute, University of
Barcelona, Barcelona, Spain; #Experimental Biophysics and Applied Nanoscience, Bielefeld
University, Bielefeld, Germany; and **Nanobioengineering Group, Institute for Bioengineering of
Catalonia, Barcelona, Spain
An important goal of nanotechnology is
the application of individual molecule handling techniques to the discovery of potential new therapeutic
agents. Of particular interest is the search for new inhibitors of metabolic routes exclusive of human pathogens,
such as the 2-C-methyl-D-erythritol-4-phosphate (MEP)
pathway essential for the viability of most human pathogenic bacteria and of the malaria parasite. Using atomic
force microscopy single-molecule force spectroscopy
(SMFS), we have probed at the single-molecule level the
interaction of 1-deoxy-D-xylulose 5-phosphate synthase
(DXS), which catalyzes the first step of the MEP pathway,
with its two substrates, pyruvate and glyceraldehyde-3phosphate. The data obtained in this pioneering SMFS
analysis of a bisubstrate enzymatic reaction illustrate the
substrate sequentiality in DXS activity and allow for the
calculation of catalytic parameters with single-molecule
resolution. The DXS inhibitor fluoropyruvate has been
detected in our SMFS competition experiments at a
concentration of 10 M, improving by 2 orders of magnitude the sensitivity of conventional enzyme activity
assays. The binding of DXS to pyruvate is a 2-step process
with dissociation constants of koff ⴝ 6.1 ⴛ 10ⴚ4 ⴞ 7.5 ⴛ
10ⴚ3 and 1.3 ⴛ 10ⴚ2 ⴞ 1.0 ⴛ 10ⴚ2 sⴚ1, and reaction
lengths of x ⴝ 3.98 ⴞ 0.33 and 0.52 ⴞ 0.23 Å. These
results constitute the first quantitative report on the use of
nanotechnology for the biodiscovery of new antimalarial
enzyme inhibitors and open the field for the identification
of compounds represented only by a few dozens of
molecules in the sensor chamber.—Sisquella, X., de
Pourcq, K., Alguacil, J., Robles, J., Sanz, F., Anselmetti,
D., Imperial, S., Fernàndez-Busquets, X. A single-molecule force spectroscopy nanosensor for the identification
of new antibiotics and antimalarials. FASEB J. 24,
4203– 4217 (2010). www.fasebj.org
ABSTRACT
Key Words: malaria 䡠 2-C-methyl-D-erythritol-4-phosphate pathway 䡠 1-deoxy-D-xylulose 5-phosphate synthase 䡠 pyruvate 䡠 glyceraldehyde-3-phosphate 䡠 drug discovery
ring at low levels in natural populations but that can
become common within a few years of the commercial
adoption of a new drug (1). The urgent need for new
efficient compounds for the treatment of disease has
stimulated the development of strategies addressed to
their identification (2). The corresponding therapeutic
targets must be, of preference, molecules that take part
in essential and exclusive processes of the pathogens
and that, therefore, do not exert pernicious side effects
on the host organism. The biosynthesis of isoprenoids,
such as sterols and ubiquinones, depends on the condensation of different numbers of isopentenyl diphosphate (IPP) units (3). In archaea, fungi, and animals,
IPP is derived from the mevalonate pathway (Fig. 1A).
In contrast, in most bacteria, algae, and in the chloroplasts of plants, IPP is synthesized by the mevalonateindependent 2-C-methyl-d-erythritol-4-phosphate (MEP)
pathway (4). The MEP pathway (Fig. 1B) begins with the
thiamine pyrophosphate (TPP)-dependent condensation
of glyceraldehyde-3-phosphate (G3P) and pyruvate to
yield 1-deoxy-d-xylulose 5-phosphate (DXP), a step catalyzed by DXP synthase (DXS) (5). Whereas the MEP
pathway is absent in mammals, it is essential for most
human bacterial pathogens (6), and thus its enzymes are
attractive targets for the development of novel antibiotics
(7). The MEP pathway has also been identified in the
apicoplast, a relict chloroplast of Plasmodium falciparum
and related parasites, where it plays an essential function
for their survival (8, 9).
Although the application of nanotechnology in the life
sciences, nanobiotechnology, is starting to have an effect
in drug discovery and development (10), this new area of
study has only had a very limited infiltration in the
research related to certain diseases specially prevalent in
developing countries. Regarding malaria, the concept of
nanotechnology is almost exclusively applied to the use of
nanoparticles for targeted drug delivery (11); to date not
1
Microbial diseases have evolved strong and devastating resistance to many antibiotics, a process occur0892-6638/10/0024-4203 © FASEB
Correspondence: Nanobioengineering Group, Institute
for Bioengineering of Catalonia, Baldiri Reixac 10-12, Barcelona E08028, Spain. E-mail: xfernandez_busquets@ub.edu
doi: 10.1096/fj.10-155507
4203
Figure 1. Scheme of the first steps of the mevalonate and MEP pathways of isoprenoid biosynthesis. A) Mevalonate pathway.
B) MEP pathway.
a single work has attempted to bring into the antimalaria
arena the powerful technique of single-molecule handling. During the past decade, single-molecule force
spectroscopy (SMFS) has developed into a highly sensitive
tool for studying the interaction of individual biomolecules (12, 13). Most SMFS experiments use either optical
tweezers or atomic force microscopy to measure dissociation forces of single ligand-receptor complexes in the
piconewton range. The binding partners are attached to
the nanoscale force sensor and a sample holder, and
when both parts are brought into close contact, a specific
link between the individual molecules is formed. By
increasing the distance between the two surfaces again,
the molecular bond is loaded under an external force
until it finally breaks, yielding the unbinding force. On
systematical variation of the externally applied load while
monitoring the mechanistic elasticity of the complex,
information can be derived about the kinetic reaction
rates, mean lifetime, equilibrium rate of dissociation,
dissociation length, and energy landscape of the interaction (14, 15). SMFS experiments have been conceived
and applied to measure interactions among single biomolecules (16), including enzyme-substrate (17–21), enzyme-inhibitor (22, 23), receptor-ligand (24 –28), antibody-antigen (29 –32), protein-DNA (33, 34), redox
partners (35), and cell adhesion molecules (36). Furthermore, intramolecular elasticity phenomena, like biopolymer structural transitions (37) and protein unfolding
(38), have been investigated by SMFS, giving access to the
study of mechanical properties of biomolecules and their
related physiological processes (39).
SMFS has been proposed as a method suitable for
screening large numbers of ligands (40), an approach
that can expedite the discovery of therapeutically useful
enzyme inhibitors in a wide affinity range. One of the
most attractive characteristics of SMFS is derived from its
ability to measure the binding force between individual
4204
Vol. 24
November 2010
enzyme-substrate molecular pairs. As a result, a soughtafter inhibitor could theoretically be detected at extremely low concentrations, especially if the inhibitor is
irreversible, which is often the most desirable case when
searching for drugs with potential pharmacological applications. An SMFS-based sensor might identify potentially
useful enzyme inhibitors remaining undiscovered because their concentrations in solution are too low to be
detected with conventional methods. Although this theoretical possibility has been hinted insistently, it has never
been put to test, and in this field SMFS has gone only as
far as being a tool for the characterization of enzymesubstrate interactions. Its real potential for the discovery
of new enzyme inhibitors has not been tapped yet, let
alone for systems having such small substrates as the
3-carbon molecules G3P and pyruvate.
Here, we have explored the capability of atomic force
microscope (AFM) SMFS to identify inhibitors of the DXS
catalytic step. The binding forces between the tethered
enzyme and either of its two substrates have been characterized at the single-molecule level, and we have studied
the sensitivity of this prototype nanosensor for the detection in solution of the DXS inhibitor fluoropyruvate (41).
Our data indicate that this proof-of-concept model system
can be developed into an efficient screening device for
the biodiscovery of new antibiotics and antimalarials.
MATERIALS AND METHODS
Unless otherwise indicated, analytical-grade reagents were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Where
the buffer composition is not indicated, the corresponding
solutions were made in bidistilled deionized water (Milli-Q
system, Millipore, Eschborn, Germany). Where the temperature is not indicated, the corresponding reactions were
incubated at room temperature.
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
Synthesis of 6-mercaptohexyl glyceraldehyde-3-phosphate
derivative
Citations of compounds 1–10 refer to Fig. 2A.
Preparation of 1-(1,3-dioxolan-2-yl)ethane-1,2-diol (compound 2)
Method is from ref. 42. An aqueous solution of KMnO4 (32 g,
200 mmol in 300 ml) was added at the rate of ⬃20 ml/min to
2-vinyl-1,3-dioxolane (30 ml, 300 mmol) (compound 1) suspended in 200 ml of water in a 3-necked 1-L flask. The mixture
was cooled in an ice bath and vigorously agitated for 2 h with a
magnetic stirrer to prevent the overoxidation that results from
the temperature exceeding 10°C. After MnO2 removal by Büchner filtration and evaporation of water, the resulting oil was
purified by distillation under reduced pressure (5 mm Hg,
136 –138°C) and obtained in a 35% yield (14.0 g). 1H-NMR (300
MHz, CDCl3) ␦ ⫽ 4.90 (d, 1H), 4.00 (m, 4H), 3.93 (m, 1H), 3.74
(d, 2H), 2.90, 3.30 (ss, OH). 13C-NMR (75 MHz, CDCl3) ␦ ⫽
103.6, 70.6, 65.8, 65.1, 63.6, 62.5.
Synthesis of 2-tert-butyldimethylsilyloxy-1-(1,3-dioxolan-2-yl)
ethane-1-ol (compound 3)
1-(1,3-Dioxolan-2-yl)ethane-1,2-diol (13.4 g, 100 mmol), previously dried by anhydrous CH3CN coevaporation, was dis-
Figure 2. Immobilization of G3P and pyruvate. A) Scheme of the synthesis of the G3P derivative 6-(pyridin-2-yldisulfanyl)hexyl
1-dimethoxytrityloxy-1-(1,3-dioxolan-2-yl)ethane 2-phosphate (compound 10). See Materials and Methods for description of the
different synthesis steps (boxed numbers), referred to as compounds 1–10 in the text. B, C) Scheme of the process followed for
the immobilization of G3P. An equimolar mix of the G3P derivative and mercaptohexanol was deposited on gold-coated mica
(B). The reaction of thiol groups with gold atoms resulted in the formation of a mixed monolayer of thethered G3P derivative
and hydroxyl-terminated chains (C). Before starting SMFS assays, the derivative was deprotected to yield tethered G3P.
D) Scheme of the process followed for the immobilization of pyruvate. APTES-silanized, freshly cleaved mica was treated first
with an NHS-PEG-MAL linker to allow for the formation of a bond between the linker NHS groups and the amino groups on
the mica surface. The resulting maleimide-functionalized surface was then overlaid with an equimolar mix of mercaptopyruvate
and mercaptoethanol to yield a mixed monolayer of tethered pyruvate and hydroxyl-terminated linker.
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
4205
solved at 1 M in anhydrous pyridine under Ar and kept in an
ice bath. TBDMS-Cl (18.1 g, 1.2 eq) was dissolved at 2 M in
anhydrous CH3CN and slowly added by cannulation to compound 2 under argon. The reaction was monitored by thinlayer chromatography (TLC) analysis and completed in 3 h.
After evaporating the solvent, workup by liquid–liquid extraction was performed by 1⫻ citric acid, 2⫻ saturated NaHCO3,
1⫻ saturated NaCl against ethyl acetate. After drying the
organic phase with MgSO4, the solvent was evaporated.
TLC and 1H-RMN analyses showed the presence of a single
product, which was obtained in a 65% yield (16.1 g, 65
mmol). 1H-NMR (300 MHz, CDCl3) ␦ ⫽ 4.90 (d, 1H),
3.95–3.82 (m, 3H), 3.69 –3.58 (m, 4H), 2.40 (bs, 1H), 0.84
(s, 9H), 0.02 (bs, 6H).
Synthesis of 1-dimethoxytrityloxy-1-(1,3-dioxolan-2-yl)ethane-2-ol
(compound 6)
Compound 3 (4.5 g, 30 mmol), previously dried by anhydrous
CH3CN coevaporation, was dissolved at 0.2 M in anhydrous
pyridine under an inert atmosphere, and dimethoxytrityl
chloride (DMTCl; 12.2 g, 36 mmol, 1.2 eq) was rapidly added.
TLC revealed that the reaction was completed after 3 h. After
evaporating the solvent, workup by liquid–liquid extraction
was performed (1⫻ citric acid, 2⫻ saturated NaHCO3, 1⫻
saturated NaCl against ethyl acetate). After drying the organic
phase with MgSO4, the solvent was evaporated. A crude
product (compound 4) was obtained and subjected to the
following deprotection step without being purified. Subsequently, the crude was treated for 3 h with tetra(tert-butyl)ammonium fluoride hydrate (TBAF, 11.4 g, 36 mmol) dissolved
in tetrahydrofuran (THF; 180 ml), and the reaction was
monitored by TLC. After solvent evaporation and workup
(1⫻ citric acid, 2⫻ saturated NaHCO3, 1⫻ saturated NaCl
against ethyl acetate), the organic phase was dried with
MgSO4, and the solvent was evaporated. The resulting products were purified by SiO2 column chromatography by elution with 60 –70% CH2Cl2 in hexane containing 1.5% Et3N.
The resulting product was obtained in a 72% yield (13.1 g, 22
mmol), and was characterized by 1H-NMR, 13C-NMR, and
MALDI. 1H-NMR (300 MHz, CDCl3) ␦ ⫽ 7.56 –7.24 (m, 9H),
6.82 (d, 4H), 4.9 (d, 1H), 3.91 (m, 4H), 3.76 (m, 1H), 3.64 (d,
2H), 2.78 (s, -OH). MALDI-EM (trihydroxyacetophenone
matrix, positive mode) m/z: 453.75 [M⫹Na]⫹, 474.78
[M⫹K]⫹. 13C-NMR (75 MHz, CDCl3) ␦ ⫽ 169.4, 158.6, 154.8,
145.3, 144.1, 135.2, 135.1, 128.3, 128.8, 127.2, 126.7, 126.6,
112.8, 102.0, 72.0, 63.8, 60.1, 54.2, 54.1.
Synthesis of 6-(pyridin-2-yldisulfanyl)hexane-1-ol (compound 5)
Method is from ref. 43. Dithiodipyridine (5.5 g, 25 mmol) was
dissolved at 0.1 M in ethanol/water (1:1) at pH 8.0, and it was
added to a 0.1 M solution of 6-mercaptohexanol in ethanol
(1.7 g, 12.5 mmol in 125 ml). After stirring for ⬃1.5 h, the
solvent was evaporated and redissolved in ethyl acetate, and
the resulting organic phase was washed with water to neutrality. The organic phase was dried with MgSO4, and after
evaporating the solvent, purification was performed by SiO2
column chromatography, eluting with a gradient from 0 to
1.5% methanol in CH2Cl2. The product was obtained as a
clear oil in a 62% yield (1.9 g, 7.8 mmol). According to NMR
analyses, no further purification was required. 1H-NMR (300
MHz, CDCl3) ␦ ⫽ 8.44 (d, 1H), 7.70 (m, 1H), 7.63 (m, 1H),
7.08 (dd, 1H), 3.62 (t, 2H), 2.79 (t, 2H), 1.71 (m, 2H), 1.53
(m, 4H), 1.36 (m, 2H).
4206
Vol. 24
November 2010
Synthesis of 6-(pyridin-2-yldisulfanyl)hexyl 1-dimethoxytrityloxy-1(1,3-dioxolan-2-yl)ethane 2-phosphate (compound 10)
Alcohol (compound 6; 800 mg, 1.9 mmol) was coevaporated
with anhydrous acetonitrile, further dried in high vacuum for
60 min, and finally dissolved in anhydrous acetonitrile at 0.1
M under an inert atmosphere. O-cyanoethyl-N,N,N⬘,N⬘-tetraisopropylphosphordiamidite (690 mg, 2.28 mmol, 1.2 eq) was
added, followed by tetrazole (66 mg, 1.0 mmol, 0.5 eq), with
continuous stirring and under extreme dry and inert conditions. The reaction was followed by TLC (ethyl acetate/
CH2Cl2/triethylamine, 45:45:10), and it was completed in
3 h. After removing the solvent by evaporation, the crude
product was redissolved in ethyl acetate, washed with aqueous
10% NaHCO3 and brine, and dried with Na2SO4. Analyses by
1
H-NMR and 31P NMR showed a mixture of phosphoramidite
isomers, which did not need further purification to carry out
the following reaction. 1H-NMR (400 MHz, CDCl3) ␦ ⫽
7.60 –7.10 (m, 9H), 6.82 (d, 4H), 3.82 (d, 1H), 4.20 –3.80 (m,
3H), 3.78 (s, 6H), 3.78 –3.20 (m, 6H), 2.72–2.42 (m, 2H),
1.40 –1.00 (m, 12H). 31P-NMR (81 MHz, CDCl3) ␦ ⫽ 148.4,
147.8.
The crude phosphoramidite (500 mg, 0.61 mmol) was
dissolved in anhydrous acetonitrile (1 ml) and compound 5
(146 mg, 0.6 mmol), and tetrazole (42 mg, 0.6 mmol) was
added. According to TLC analysis (ethyl acetate/CH2Cl2/
triethylamine, 45:45:10), the coupling (compound 8) was
completed in 5 h. The mixture was then treated with 0.5 ml of
6 M tBuOOH/toluene to produce oxidation of phosphite to
phosphate, to obtain compound 9. The solvent was evaporated, and the resulting crude product was dissolved in 20 ml
of 7 N NH3 in methanol to produce the cyanoethyl group
removal and the obtainment of compound 10. The solvent
was again evaporated, and the crude product was purified first
by precipitation in cold hexane and subsequently by SiO2
column chromatography (gradient from 0.2 to 20% methanol in CH2Cl2). Product was obtained as a clear oil in a 14%
yield, and it was characterized by 1H-NMR, 31P-NMR, and
electrospray mass spectrometry. 1H-NMR (400 MHz, CDCl3)
␦ ⫽ 8.47 (d, 1H), 7.71 (d, 1H), 7.62 (t, 1H), 7.51 (d, 2H), 7.39
(d, 4H), 7.25–7.18 (m, 3H), 7.06 (dd, 1H), 6.80 (d, 4H), 5.49
(m, 1H), 3.88 –3.77 (m, 3H), 3.63 (t, 2H), 3.48 (s, 6H),
3.47–3.20
(m, 4H), 2.80 (t, 2H), 1.72–1.30 (m, 10H). 31P-NMR (81
MHz, CDCl3) ␦ ⫽ 0.60. ESI-MS (negative mode) m/z 740.5
[M-H]⫺, 740.5 [M⫹Na-2H]⫺.
Construction of the Escherichia coli DXS expression vector
pET-23-DXS
The coding region of E. coli DXS (64 kDa), cloned into the
expression vector pT7–7 (44), was amplified by PCR using Pfu
DNA polymerase and primers T7 (5⬘-TAATACGACTCACTATAGG-3⬘) and pET-23-XhoI (5⬘-CGCTCGAGTCCTGCCAGCCAGGCCTTGATTTTGGC-3⬘). After digestion with NdeI and
XhoI, the amplified DNA fragment was ligated into the same
sites of the expression vector pET-23b. Strain DH5␣ (Promega, Madison, WI, USA) was used as the recipient during
this transformation. Positive clones were identified by DNA
sequencing using Big Dye Terminator v3.1 cycle sequencing
kit (Applied Biosystems, Foster City, CA, USA). The resulting
plasmid was designated pET-23-DXS, which produces the
C-terminal histidine-tagged protein.
Overexpression and purification of E. coli DXS
BL21 (DE3) pLysS cells carrying pET-23-DXS were grown in
Luria-Bertani medium supplemented with 100 g/ml ampi-
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
cillin and 34 g/ml chloramphenicol at 22°C to an OD600 of
0.3– 0.4 and then induced with 0.3 mM isopropyl -d-thiogalactoside for 18 –20 h. Bacterial cells were recovered by
centrifugation, and the cell pellet was resuspended in 40 mM
Tris-HCl buffer, pH 8.5, containing 100 mM NaCl, 10 mM
imidazole, 1 mM MgCl2, 5 mM -mercaptoethanol, 1 mM
TPP, 1 mg/ml lysozyme, 1 mM Pefabloc SC Plus (Roche,
Basel, Switzerland), and one tablet of complete EDTA-free
protease inhibitor cocktail (Roche). After incubation at 4°C
for 30 min the lysate was sonicated during 20 s and centrifuged at 12,000 g for 45 min at 4°C. Recombinant DXS was
purified by Ni2⫹ affinity chromatography (1 ml Hi-Trap
chelating column, GE Healthcare, Little Chalfont, UK) with a
linear gradient from 10 to 500 mM imidazole. Fractions
containing DXS were pooled; dialyzed against a buffer containing 50 mM Tris-HCl (pH 7.5), 137 mM NaCl, 1% Tween
20, and 1% Triton X-100; snap-frozen in liquid N2; and finally
stored at ⫺80°C until use. Protein concentration was determined by the method of Bradford (45), using bovine serum
albumin as standard.
Immobilization of molecules for SMFS
Pyruvate
Freshly cleaved muscovite mica slides (Metafix, Montdider,
France) were gas phase silanized with (3-aminopropyl)triethoxysilane (APTES) in a vacuum desiccator according to
established protocols (46), and overlaid with 1 mM N-succinimidyl-6-maleimido caproate overnight. The resulting maleimide groups were used to bind the thiol groups in mercaptopyruvate and mercaptoethanol (added as a 1 mM
equimolar mix) to yield a layer of immobilized pyruvate.
Surface-bound mercaptoethanol provided a hydrophilic environment in the bidimensional molecular film.
G3P
An equimolar mix of compound 10 and mercaptohexanol (1
mM each in 100% EtOH) was directly deposited overnight
onto gold-coated mica surfaces prepared with the templatestripped gold method (47). The reaction between the SH
group generated on the G3P derivative and Au atoms formed
a layer of immobilized G3P after treatment with 50%
CH3COOH for 30 min to remove protecting DMT and ketal
groups. Mercaptohexanol bound to the surface through its
thiol group provided a hydrophilic environment in the bidimensional molecular film.
DXS
APTES-silanized silicon nitride tips (Olympus Corp., Tokyo, Japan) were first modified with a combination of
bifunctional linkers. Tips were immersed overnight in a 1
mM solution of N-hydroxysuccinimide-polyethyleneglycolmaleimide (NHS-PEG-MAL) 3400 linker (polydispersity
index ⬍1.05; Nektar, Huntsville, AL, USA), rinsed, and then
treated with a 1 mM 11-mercaptoundecanoic acid solution in
EtOH. The carboxyl-functionalized tips were then activated
using NHS and N-ethyl-N⬘-(3-diethylaminopropyl)carbodiimide
(EDC) coupling (48). The resulting NHS group reacted with
the amino groups from the side chains of Lys residues in DXS,
which was added in SMFS assay buffer (see below) at a
concentration of 70 g/ml. After 1 h, unreacted ester
groups were finally capped with a brief immersion in 1 M
ethanolamine-HCl, pH 8.0.
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
AFM imaging
Tapping-mode AFM images were taken in 2.5 mM MgCl2, 1
mM TPP, and 40 mM Tris-HCl (pH 8) with a Molecular Force
Probe 3D microscope (Asylum Research, Santa Barbara, CA,
USA). Silicon nitride tips mounted on pyramidal 200-m
cantilevers (k ⫽ 0.02 N/m) were purchased from Olympus.
Frequency was set to 5–10% lower than resonance, with a free
amplitude of 1 V and a set point kept below 20% of free
amplitude.
Immobilization of DXS on synthetic beads
DXS (2.5 mg/ml), dissolved in 140 mM NaCl, 1% Tween 20,
1% Triton X-100, and 50 mM Tris-HCl (pH 7.5), was passed
through a protein desalting column equilibrated with 100
mM MOPS (pH 6.4), and finally immobilized onto synthetic
beads containing a NHS ester at the end of a 10C spacer arm
(AffiGel 10; Bio-Rad, Hercules, CA, USA). Desalted enzyme
(2.25 ml) was added to 100 l of beads prewashed with 10
mM sodium acetate (pH 4.5), and after 1 h incubation, the
mix was centrifuged, and the supernatant was removed.
Unreacted sites were blocked by treatment for 1 h with 1 M
ethanolamine-HCl, pH 8.0. Pelleted beads (40 l) were used
for enzyme activity assays.
Time-of-flight secondary ion mass spectroscopy (TOF-SIMS)
characterization of immobilized pyruvate and G3P
Positive polydimethylsiloxane stamps (5-m-diameter cylindrical posts) were immersed for 5 min in 1 mM solutions of
mercaptopyruvate or compound 10. Stamps with the adsorbed molecules were then dried under N2 flow and microcontact printed on mica and gold surfaces functionalized as
described above for SMFS assays. TOF-SIMS analyses were
performed using a TOF-SIMS IV (ION-TOF GmbH, Münster,
Germany) operated at a pressure of 5 ⫻ 10⫺9 mbar. Samples
were bombarded with a pulsed bismuth liquid metal ion
source (Bi3⫹), at an energy of 25 keV. The gun was operated
with a 20-ns pulse width, 0.3-pA pulsed ion current for a
dosage lower than 5 ⫻ 1011 ions/cm2, well below the threshold level of 1 ⫻ 1013 ions/cm2 generally accepted for static
SIMS conditions. Secondary ions were detected with a reflectron TOF analyzer, a multichannel plate, and a time-to-digital
converter (TDC). Measurements were performed with a
typical acquisition time of 20 s, at a TDC time resolution of
200 ps. Charge neutralization was achieved with a low-energy
(20-eV) electron flood gun. Secondary ion spectra and images in both positive and negative mode were acquired from
randomly rastered surface areas of 500 ⫻ 500 m along the
microslide. Secondary ions were extracted with 2 kV voltage
and postaccelerated to 10 keV kinetic energy just before
hitting the detector. The maximum mass resolution, r ⫽
m/Dm, was ⬃ 9000, where m is the target ion mass and Dm is
the resolved mass difference at the peak half-width.
Surface plasmon resonance (SPR)
SPR assays were done in a T100 SPR instrument (Biacore, GE
Healthcare) using CM5 sensor chips for the immobilization
of pyruvate and G3P through thiol groups. NHS, EDC, and
2-(2-pyridinyldisulfanyl)ethaneamine (PDEA) were also obtained from Biacore. Equal volumes of 50 mM NHS and 200
mM EDC were mixed together, and 20 l of the resulting
solution were injected at 10 l/min into the flow cell of the
sensor chip. For the immobilization of pyruvate, 40 l of 80
mM PDEA was injected, followed by 50 l of 50 mM mercaptopyruvate, and finally by 40 l of 50 mM 2-mercaptoethanol
4207
to cap unreacted activated sites. For the immobilization of
G3P, 40 l of 40 mM cystamine (pH 8.5) was injected,
followed by 40 l of 0.1 M dithioerythritol, and finally by 50
l of a 50 mM solution in 70% EtOH of the G3P derivative
compound 10. The remaining unreacted sites where finally
capped with 40 l of 1 M NaCl and 20 mM PDEA, pH 4.0.
DMT and ketal-protecting groups were removed with 40 l of
a 100 mM HCl, 1 M NaCl solution, also used to regenerate the
chip surfaces by flushing it for 30 s at a flow rate of 30 l/min.
For the control flow cell, the NHS/EDC-activated chip surfaces were flushed with 40 l of an 80 mM ethanolamine-HCl
solution to cap all the reacting sites.
SPR assays were performed at 20°C in running buffer (150
mM NaCl, 2.5 mM MgCl 2, and 10 mM HEPES, pH 7.4).
Enzyme solutions in running buffer containing 1 mM TPP
were injected at 15 l/min during 100 s, with DXS alone or in
the presence of different concentrations of pyruvate, fluoropyruvate, or G3P. Data were recorded from 30 s before
injection start to 200 s after the end of injection. Biacore T100
1.1 evaluation software was used for analysis, which enabled a
double blank subtraction from two control samples: enzymecontaining solution flushed through the control cell and
buffer without enzyme flushed through immobilized pyruvate- and G3P-containing cells. Rate and equilibrium constants were obtained by analyzing the kinetics of binding with
the analysis software for biosensor data Scrubber2 (BioLogic
Software Pty. Ltd., Campbell, Australia).
DXS activity determination
DXS enzymatic activity was usually determined by a spectrophotometrical assay using purified 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR) as coupled enzyme (49).
Recombinant E. coli DXR was obtained as described elsewhere
(50). All kinetic measurements were made at 37°C in triplicate. The standard reaction mixtures were done in 100 mM
Tris-HCl buffer (pH 7.8) containing 1 mM TPP, 1 mM MgCl2,
1 mM MnCl2, 1 mM DTT, 0.15 mM NADPH, 1 mM pyruvate,
1 g DXS, and 6 g DXR in a final volume of 0.2 ml. The
reaction was initiated by adding 1 mM dl-glyceraldehyde
3-phosphate. Initial reaction velocities were determined following the oxidation of NADPH by monitoring A340 in a
Benchmark Plus spectrophotometer (Bio-Rad). One enzyme
unit is defined as the amount of DXS catalyzing the transformation of 1 mol of pyruvate and d-glyceraldehyde 3-phosphate into DXP under the conditions of the assay. As an
alternative method for DXS activity analysis, we used TLC on
60 F254 Silicagel plates (Merck, Wilmington, DE, USA)
[MeOH/H2O/25% (v/v) NH3/CH3COOH, 50:25:7.5:1],
stained with -anisaldehyde/sulfuric acid/acetic acid (2.4%:
3.6%:1.2%, v/v) (51).
Force spectroscopy measurements
Force spectroscopy studies were performed in a Molecular
Force Probe 3D microscope (Asylum Research, Santa Barbara, CA, USA). Silicon nitride tips mounted on triangular
200-m cantilevers (k ⫽ 0.02 N/m) were purchased from
Olympus. The spring constant of every tip was individually
measured through the equipartition theorem using the thermal noise of the cantilever (52). SMFS assays were performed
in 2.5 mM MgCl2, 1 mM TPP, 40 mM Tris-HCl, pH 8. The
configurations used consisted of DXS on the cantilever,
pyruvate or G3P on mica or gold surfaces, respectively, and
the buffer alone or buffer containing substrates or fluoropyruvate. The cantilever was lowered to the surface manually,
and the AFM was operated such that it moved away from and
then toward the sample surface during the course of each
4208
Vol. 24
November 2010
cycle. The pressure applied at the contact point was ⬍1 nN.
Based on preliminary assays performed at different loading
rates, the SMFS data presented were obtained with a pulling
velocity of 0.5 m/s, except where otherwise indicated. The
same tip and surface were used with the different substrate
and inhibitor solutions of a single experiment. For each
configuration, 1500 force plots were recorded and taken at
different points on the functionalized surfaces. Data analysis
and statistical treatments were done with the software provided by the AFM manufacturer (IgorPro 5.0.4.8; WaveMetrics Inc., Lake Oswego, OR, USA). To restrict the analysis to
single-molecule interactions, peak selection was generally
done manually, setting a maximum length threshold of 100
nm (which corresponds to the maximum length of the PEG
linker), considering only the last adhesion event of forceextension curves. Force curves with peaks above 1 nN were
likely arising from non-specific adhesions, and we did not
consider them as enzyme-substrate interactions, although
they were included in the statistics calculations as curves
without specific binding event.
RESULTS
The planned configuration of SMFS assays consisted
of DXS-functionalized AFM cantilevers and pyruvateor G3P-functionalized surfaces via heterobifunctional linkers (32). Such strategy introduces a distance between interacting molecules and surfaces,
adds steric flexibility for the binding partners, and
guarantees an almost complete reduction of unspecific
binding events (53), although it might affect the calculation of the apparent kinetic and thermodynamic
enzymatic parameters (23). Because E. coli DXS has 36
lysines, of which only K289 is present in the active
center (54), we followed established protocols (48) for
the covalent linkage of the enzyme to SiN3 cantilevers
through the lateral amino group in lysine residues,
using a monodisperse ⬃100 nm-long polyethylene glycol (PEG) linker (Fig. 3). As shown below, DXS immobilized in this way was active in binding its two substrates, pyruvate and G3P. The immobilization of G3P
was done through its phosphate based on data reporting that this group is exposed to the solvent and does
not participate in the enzymatic reaction (54). Thus, a
G3P derivative containing a gold-reacting linker was
synthesized (Fig. 2A) and deposited onto gold-coated
mica surfaces to obtain self-assembled monolayers
(SAMs) of the G3P derivative following reduction of
disulfide groups by gold (Fig. 2B, C). To obtain pyruvate SAMs, (3-aminopropyl)triethoxysilane-silanized
flat mica surfaces were functionalized with mercaptopyruvate through a maleimido-PEG-N-hydroxysuccinimide linker (Fig. 2D). The choice of the thiol group
located in the C3 atom of mercaptopyruvate for the
immobilization of the substrate was made on the basis
of data showing that this carbon is not implicated either
in the initial formation of the adduct with TPP or in the
forthcoming steps of the reaction mechanism (4, 54).
Additional experimental evidence validating our strategy indicated that DXS was active in metabolizing
hydroxypyruvate instead of pyruvate (55), which sug-
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
Figure 3. Immobilization of DXS on AFM cantilevers. A) Treatment of silanized AFM cantilevers
with NHS-PEG-MAL and 11-mercaptoundecanoic
acid linkers to generate a carboxyl-terminated
tether. B) Activation of the carboxyl group with
EDC/NHS to make it reactive with amino lateral
groups in DXS. C) Scheme of DXS immobilization
on AFM cantilevers.
gests that an additional group in C3 did not affect the
enzyme-substrate interaction.
TOF-SIMS (56) was used to characterize the correct
immobilization of pyruvate and G3P on mica and gold
surfaces, respectively (Fig. 4). A fragment of 74.97 Da
was consistent with the presence of pyruvate after the
crosslinking procedure onto mica (Fig. 4A). Other
molecules detected were a sulfur-containing derivative
(60.96 Da) and a part of the bifunctional linker (198.85
Da). Measures of G3P patterns on gold detected the
presence of phosphates (97.29 Da), thiopyridine
(110.35 Da), and different species originated from the
synthesized G3P derivative (at 623.70, 632.20, and
765.06 Da) (Fig. 4B).
Bidimensional on-the-surface dilution of pyruvate
and (after deprotection of the derivative) G3P in a
hydrophilic environment was achieved by introduction
of hydroxyl-terminated linkers to form mixed SAMs
that reduced sterical hindrances between the interacting molecules in SMFS experiments (Fig. 5A, B). AFM
imaging of surfaces, functionalized with pyruvate, G3P,
or DXS following the chemistry described above,
showed the deposition of homogeneous monolayers
(Fig. 5C–E), with root mean square roughness of 0.7,
1.1, and 1.3 nm, respectively. Binding between DXS
and its substrates crosslinked to surfaces was first explored by surface plasmon resonance (SPR). Mercaptopyruvate and the G3P derivative were bound to SPR
chips with the same chemistry used later in SMFS assays,
to yield immobilized pyruvate and G3P. DXS in solution binds efficiently to both tethered substrates in a
concentration-dependent process (Fig. 5F, G). Complete dissociation was not achieved in either case, in
agreement with the existence of a strong interaction
between DXS and its two covalently immobilized substrates. Different substrate concentrations were assayed,
which provided optimal pyruvate and G3P densities of
65 and 780 response units, respectively. Higher densiINDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
ties resulted in reduced DXS binding, probably because
of steric hindrance due to densely packed substrate
layers. The integrated rate equations were fitted to the
association and dissociation sensorgrams (57), obtaining both on- and off-rate constants, and thus the
equilibrium dissociation constants, KD,pyruvate ⫽ ⬃57
M and KD,G3P ⫽ ⬃81 M, whose values did not differ
significantly from those derived from enzyme assays in
solution (100 and 440 M, respectively) (58).
The measured rupture force of the interaction between DXS tethered to AFM cantilevers and surfacebound pyruvate was found to be between 150 and 250
pN, depending on the loading rate (Figs. 5H and 10B).
To estimate the time and number of approach/retract
curves during which the enzyme maintained its activity, we
routinely performed controls where the binding probability for a given system configuration was checked throughout control experiments. The binding probability (%) was
calculated as the number of force curves with ⱖ1 specific
enzyme-substrate adhesion event vs. the total number
of curves. The data obtained indicated that DXS bound
its immobilized substrates without decrease in rupture
force or binding probability for a time between 6 and
8 h, or 6000 recorded curves. Specific adhesion events
were indicated by analysis of the force curves immediately before the jump-off contact. Specific interactions
are characterized by a typical worm-like chain slope in
the adhesion zone of the retracting plot just before
rupture (Fig. 5H) (12, 22). Such an analysis is greatly
facilitated by the use of suitable flexible linkers connecting the inorganic surfaces with the biomolecules.
In addition, we considered only ruptures that took
place at a distance from the surface ⬍100 nm, which
corresponds approximately to the linker length. Examples of multiple-peak curves and of unspecific tipsurface binding are provided in Fig. 6. Finally, force
peaks above 1 nN were not considered because they
were relatively few and far off the gaussian median
4209
Figure 4. TOF-SIMS analysis of tethered pyruvate immobilized
on mica (A) and of tethered G3P immobilized on gold (B).
centered at ⬃200 pN in control experiments. Other
controls involved testing the DXS-free PEG linker on
substrate-functionalized surfaces. In such assays, the
force distributions obtained lacked the 200 pN maximum and presented instead a few events distributed
below and above this value (Fig. 7), resulting from
4210
Vol. 24
November 2010
unspecific linker-surface interactions. Because of the
large difference in molecular mass between the PEG
linker and DXS (3.4 and 64.0 kDa, respectively), the
unspecific adhesion events experienced by the PEG
linker alone will be reduced ⬃20-fold in the presence
of DXS. Force plots in competition SMFS assays indicated that maximal adhesion probability between DXS
and G3P was obtained on addition of soluble pyruvate
(Fig. 8A), yielding rupture forces similar to those for
the DXS-pyruvate association. These data are consistent
with SPR results showing that the presence of soluble
pyruvate increased the interaction of DXS with a G3Pfunctionalized surface (Fig. 8B). The presence of TPP
in solution was necessary in SPR assays for the detection
of binding between DXS and G3P (Fig. 8B) or pyruvate
(Fig. 8C), whereas in SMFS experiments, the interaction of the enzyme with either substrate was not dependent on the presence of the cofactor.
Competition SMFS assays in the presence of 1 mM
pyruvate showed that soluble G3P interfered with the
adhesion of DXS to immobilized G3P in a concentration-dependent process (Fig. 8D), with a significant
inhibitory effect at 0.1 mM G3P. In contrast, 1 mM
soluble pyruvate had to be present to decrease the
probability of DXS binding to immobilized pyruvate
(Fig. 8E). In this case, the addition of soluble G3P did
not increase the binding probability between DXS and
pyruvate (data not shown). As a routine control performed at the end of each SMFS assay, force peaks were
recovered on removal of the soluble competitor, confirming DXS performance and validating the data
obtained. More complex force distributions were often
obtained in some SMFS experiments (Fig. 8D, E, G),
usually in the form of adhesion peaks at ⬃400, 600, and
800 pN, which might represent simultaneous multiple
binding events. In agreement with SMFS data, SPR
competition assays for the binding of DXS between
immobilized pyruvate and soluble pyruvate or the enzyme inhibitor fluoropyruvate at high concentrations
showed that the presence of soluble ligands decreased
the affinity of the enzyme for the homologous surfacebound substrate (Fig. 8C). SMFS binding competition
assays in the presence of soluble fluoropyruvate at
lower concentrations showed that the DXS inhibitor
was significantly more efficient than soluble pyruvate in
blocking the interaction with immobilized pyruvate.
The presence of 0.1 mM fluoropyruvate (Fig. 8F)
reduced to 2% the binding probability between the
enzyme and surface-bound pyruvate, whereas 1 mM
fluoropyruvate was necessary to inhibit DXS binding to
G3P (Fig. 8G). Sensitivity could be improved by reducing the amount of immobilized DXS on the AFM
cantilever. For the configuration DXS-pyruvate, using
100 times less enzyme resulted in a 10-fold sensitivity
increase, with 10 M fluoropyruvate reducing by ⬎85%
the DXS-pyruvate interaction (Fig. 9A).
Although the covalent immobilization of DXS did
not abolish the binding to its substrates, we had no
information on how this affected the metabolic competence of the enzyme. To explore this issue we per-
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
Figure 5. DXS binding to covalently immobilized pyruvate and G3P. A) Scheme of mica
surfaces functionalized with pyruvate (boxed
and shaded). B) Scheme of gold surfaces functionalized with G3P (boxed and shaded). C–E)
AFM images of pyruvate-coated mica (C), G3Pcoated gold (D), and DXS immobilized on mica
with the same chemistry used for its binding to
cantilevers (E). Vertical z scale is 20 nm. Representative cross-section analysis of surface roughness is presented at bottom of each image.
F, G) SPR assays of DXS binding to its immobilized substrates. F) G3P binding analysis: 1⫻ ⬃
37 g/ml. G) Pyruvate binding analysis: 1⫻ ⬃
46 g/ml. All samples contained 1 mM TPP.
H) Typical approach-retract SMFS force cycle
for a single DXS-pyruvate binding event.
formed enzyme activity assays with DXS crosslinked to
N-hydroxysuccinimide-functionalized agarose beads with the
same chemistry as that used for SMFS experiments.
Thin-layer chromatography analysis of the reaction
products revealed the presence of DXP (Fig. 10A),
indicating that tethered DXS could metabolize its substrates, although a quantitative estimation showed that
the immobilized enzyme retained only ⬃14% of its
catalytic activity in solution.
Pulling experiments in which the tip-surface separation speed is changed in such a way that the force per
unit time (loading rate) acting on the molecular bond
under study is changed over orders of magnitude are
referred to as dynamic force spectroscopy (DFS). DFS
permits a deeper analysis of the mechanics of singlemolecule assays, providing information on dissociation
constants and the average lifetimes of molecular interactions. According to the standard model of thermally
driven dissociation under external force (14), the measured dissociation forces (Fmax) depend on the experimental retraction velocity and should be represented
against the corresponding loading rates in a DFS plot.
To obtain molecular loading rates, the retraction velocity is multiplied by the elasticity of the system, which is
determined by fitting the slope of every single force
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
curve just before dissociation. Generally, the measured
Fmax obeys the following law (Eq. 1):
F max ⫽
x r
kB T
ln
x
kB T koff
(1)
where kBT and r denote thermal energy and the loading
rate, respectively. x is a length parameter along the
reaction coordinate representing the distance between
the minimum of the binding potential and the transition state separating bound and free states, which is
commonly referred to as the reaction length. koff is the
thermal off-rate constant under zero external load and
can be deduced by linearly extrapolating the experimental data in the DFS plot to zero external force
(F⫽0). The inverse relation of koff to the average
lifetime of the complex, (koff ⫽ ⫺1), allows a direct
way of evaluating its stability. For the interaction
DXS-pyruvate, when we applied mechanical force in
a range of loading rates, the logarithmic DFS plot of
the measured SMFS data shows the presence of two
force regimes according to Eq. 1 (Fig. 10B). For the
single-molecule process, quantitative analysis at low
and high loading rates yields, respectively, dissociation
constants of koff ⫽ 6.1 ⫻ 10⫺4 ⫾ 7.5 ⫻ 10⫺3 and 1.3 ⫻
4211
the affinity of the enzyme for the second substrate,
G3P, which is required for the catalysis to proceed.
SMFS data indicate that the interaction of DXS with G3P
and pyruvate remains unchanged regardless of the presence of TPP, in opposition to SPR assays where the
cofactor is required for the retention of the enzyme on
the substrate layer. These apparently contradictory results
suggest that parameters derived from techniques that
analyze molecular populations cannot be extrapolated
directly to predict the behavior of individual molecules.
Whereas biomolecules in conventional ensemble assays
are interrogated simultaneously in large numbers and
average properties are extracted, in single molecule
experiments they are probed one at a time, gaining
access to new types of information. The interaction of
DXS with its substrates might be too brief in the
absence of TPP to allow a measurable DXS layer
deposition on the substrate-coated SPR chip, but long
enough to be detected by SMFS as a brief binding
event. In the case of pyruvate:
关DXS兴 ⫹ 关Pyr兴
关DXS-Pyr兴
SMFS
detection
(2)
Figure 6. Examples of SMFS force-extension graphs for the
DXS-pyruvate binding analysis. Top graph corresponds to a
pull with multiple interactions where the last peak on the left
was considered to be a specific adhesion event. Middle graph
was discarded because of a dissociation length ⬎100 nm, the
maximum expected system stretching according to the
known linker lengths. Bottom graph is characteristic of a
short-range, nonelastic, unspecific tip-surface interaction.
10⫺2 ⫾ 1.0 ⫻ 10⫺2 s⫺1, and reaction lengths of x ⫽
3.98 ⫾ 0.33 and 0.52 ⫾ 0.23 Å.
DISCUSSION
DXS belongs to a subclass of TPP-dependent enzymes
that combine characteristics of decarboxylases and
transketolases. A reaction mechanism has been proposed (41) involving formation of a highly reactive TPP
ylide, nucleophilic attack of the ylide on the donor
substrate (pyruvate), elimination of the first product
(CO2), nucleophilic attack of the ␣-carbanion/enamine on the acceptor substrate (G3P), elimination of the
second product (DXP), and regeneration of TPP. Our
data obtained at single-molecule resolution confirm the
sequentiality in the incorporation of both substrates
into the active center, evidenced by the requirement of
soluble pyruvate for maximal DXS-G3P binding but not
of soluble G3P for maximal DXS-pyruvate interaction.
Moreover, CO2 trapping experiments showed that DXS
does not efficiently catalyze the decarboxylation of
pyruvate and release of CO2 in the absence of G3P
(41), indicating that the binding of G3P is required to
form a catalytically competent complex. On the basis of
these results, an ordered mechanism can be proposed
where entry of pyruvate in the active center increases
4212
Vol. 24
November 2010
关DXS-Pyr-TPP兴
关DXS-TPP*兴
SPR
detection
Our data lead us to propose that, in the absence of
TPP, the transiently formed DXS-pyruvate complex
quickly dissociates; whereas in the presence of TPP, the
equilibrium is displaced toward a relatively stable species involving DXS, pyruvate, and TPP. Under adequate
conditions, probably not met by crosslinked substrates,
this ternary complex undergoes decarboxylation and is
ready to transfer the acetyl group to G3P. In this
scenario, the ternary complex DXS-pyruvate-TPP, but
not the short-lived DXS-pyruvate species, might have a
sufficiently low dissociation rate to allow for the formation of a significant molecular layer amenable to SPR
detection. SMFS, however, could likely detect the presence of the labile DXS-pyruvate intermediate in a
significant number of the 1-s cycles of each experiment.
This finding highlights the potential of single-molecule
analysis to unravel molecular phenomena that escape
detection when studied by other techniques. The proposed stability of the ternary complex DXS-pyruvateTPP would explain our SPR data where, after the
Figure 7. Control assay of the effect of the PEG linker on
unspecific SMFS interactions. A pyruvate-coated surface was
probed with cantilevers functionalized with PEG-DXS or only
with PEG. Corresponding histograms were fitted to gaussian
curves.
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
Figure 8. Analysis of the interaction of DXS with pyruvate and G3P in SMFS assays. A) SMFS analysis of the effect of soluble
pyruvate on the interaction between immobilized DXS and G3P. Percentages represent frequency of binding events in the
different experimental configurations. Temporal sequence from top to bottom: no soluble pyruvate, addition of 1 mM pyruvate,
removal of soluble pyruvate. B) Effect of the presence of soluble TPP, G3P, and pyruvate on the SPR analysis of DXS binding
to a G3P-coated chip. All samples contained 1 mM TPP, except DXS ⫺ TPP. C) SPR analysis of the effect of fluoropyruvate on
the binding between DXS and pyruvate. All samples contained 1 mM TPP, except DXS ⫺ TPP. D) SMFS analysis of the effect
of soluble G3P on the binding between immobilized DXS and G3P. All samples contained 1 mM pyruvate. Temporal sequence
from top to bottom: no soluble G3P, addition of 0.1 mM G3P, addition of 1 mM G3P, removal of soluble G3P. E) SMFS analysis
of the effect of soluble pyruvate on the binding between immobilized DXS and pyruvate. Temporal sequence from top to bottom: no
soluble pyruvate, addition of 0.1 mM pyruvate, addition of 1 mM pyruvate, removal of soluble pyruvate. F) SMFS analysis of the effect
of soluble fluoropyruvate on the binding between immobilized DXS and pyruvate. Temporal sequence from top to bottom: no soluble
fluoropyruvate, addition of 0.1 mM fluoropyruvate, removal of soluble fluoropyruvate. G) SMFS analysis of the effect of soluble
fluoropyruvate on the binding between immobilized DXS and G3P. All samples contained 1 mM pyruvate. Temporal sequence from
top to bottom: no soluble fluoropyruvate, addition of 1 mM fluoropyruvate, removal of soluble fluoropyruvate.
association phase, rinsing the surface with buffer did
not induce a rapid decrease of the signal. Maintenance
of the interaction between DXS and tethered pyruvate,
accounting for the sustained SPR signal, could result
from a blockage in the reaction due to the presence of
the linker in place of the pyruvate methyl group.
Although the methyl group does not participate in the
catalysis, the presence of a linker might introduce steric
hindrances preventing progress of the reaction. The
same reasoning can be applied to SPR results obtained
with immobilized G3P.
One of the principal challenges of understanding
enzyme catalysis is resolving the dynamics of enzymesubstrate interactions with ångström resolution, the
length scale at which chemistry occurs (59). The two
force regimes detected in DFS plots for the interaction
DXS-pyruvate suggest the existence of a first step involving the formation of a relatively stable complex with a
mean dissociation length of ⬃4 Å, which might correspond to the initial recognition between the enzyme
and its first substrate. A second, unstable, complex with
a mean dissociation length ⬍1 Å could reflect atomic
interactions involved in bond formation. An interesting
observation with regard to the future development of a
nanosensor device is the ability of tethered DXS to
efficiently bind its two substrates without having a very
high catalytic activity. Current activity assays used to
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
detect inhibitors invariably need metabolically active
enzymes, whereas the data presented here indicate that
SMFS-based nanosensors might only require enzyme
binding to the substrates, without the need for product
synthesis. This finding suggests a dissociation of DXS
activity between substrate recognition properties, which
are retained by the tethered enzyme, and substrate
transformation, which seemingly depends significantly
on the presence of an intact enzyme. The strategy used
to immobilize DXS on the AFM tip could have altered
the chemical neighborhood of some key reactive
groups, or it might have rendered the enzyme less free
to adapt by induced fit to its substrates.
Enzyme inhibition is the major mechanism of action of
many drugs, including antiinflammatory (60), antihypertensive (61), antineoplastic (62– 65), antidepressant (66),
antiasthmatic (67), anti-Parkinson (68), anti-Alzheimer
(69 –71), lipid-lowering (72), anti-AIDS (73,74), and antimicrobial compounds (4, 6, 7). The absence of the MEP
pathway in animals suggests that inhibitors of its enzymes
can be used at relatively high concentrations to treat
certain bacterial and protozoan infections without exhibiting undesired side-effects. In addition, this will lead to a
higher efficiency of the drug and, in turn, to a reduction
in the appearance of resistant strains typically observed
when a drug is administered at sublethal doses for an
extended period. Microbes often can revert a blocked
4213
Figure 9. High-sensitivity single-molecule nanosensor for the detection of DXS inhibitors. A) SMFS analysis of the effect of
soluble fluoropyruvate on the binding between immobilized DXS and pyruvate, using a DXS concentration 100 times smaller
than that in Fig. 8F. Temporal sequence from top to bottom: no soluble fluoropyruvate, addition of 1 M fluoropyruvate,
addition of 10 M fluoropyruvate, removal of soluble fluoropyruvate. B) Configuration showing the interaction between DXS
bound to nanoscale sensor and pyruvate to mica surfaces. C) A significant decrease in the binding of DXS to the
pyruvate-functionalized surface indicates the presence of an inhibitor in solution.
pathway through the recruitment of enzymatic activities
that participate in similar reactions and that, by means of
mutations that alter their substrate specificity or their
expression levels, can metabolize alternative substrates
into intermediaries located downstream of the blocked
step. A second characteristic that makes the MEP pathway
a particularly suitable target for the development of
antibiotics derives from the observation that when its steps
are blocked very low rates of reversion are observed (75).
Fosmidomycin, an inhibitor of DXP reductoisomerase,
the second enzyme of the MEP pathway, has shown
4214
Vol. 24
November 2010
antimalarial activity in vitro and in murine malaria models
(76), and early clinical studies have now proven its efficacy
and safety in the treatment of uncomplicated P. falciparum
malaria in humans (77). It can be foreseen that by
selectively blocking other MEP pathway steps a similar
effect to that observed for fosmidomycin will be found
and that some of the compounds inhibiting these enzymes would also act on the parasite (7). In agreement
with this view, the DXS inhibitor fluoropyruvate was
proposed as a putative antimalarial drug (41).
Pyruvate, with a molecular mass of only 88 Da, is to
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
of compounds represented only by a few dozens of
molecules in the sensor chamber.
Figure 10. Calculation of enzymatic parameters. A) TLC
analysis of the activity of DXS crosslinked to agarose beads.
B) Dynamic force spectroscopy graph for the interaction
between immobilized DXS and pyruvate in SMFS assays,
where the measured dissociation forces are plotted against
the loading rate.
This work was supported by grants BIO2002-00128,
BIO2002-04419-C02-02, BIO2005-01591, BIO2008-01184,
CSD2007-00036, and CSD2006-00012 from the Ministerio de
Ciencia e Innovación, Spain, which included FEDER funds,
and by grants 2009SGR-760, 2009SGR-0026, and 2005SGR00914 from the Generalitat de Catalunya, Spain. We thank
the Nanotechnology Platform of the Barcelona Scientific
Park and Marta Taulés (Scientific and Technical Services of
the University of Barcelona) for technical assistance.
REFERENCES
1.
2.
date the smallest substrate that has been immobilized
in an active form for its use in dynamic force spectroscopy assays, thus expanding the powerful applications
of this technique to the study of the interactions of very
small molecules. The strategy used to covalently crosslink G3P through its phosphate group into surfaces in
a form adequate for recognition by its metabolizing
enzyme opens the field to single-molecule analysis of
similarly reactive phosphate-containing enzyme substrates. Using pyruvate as the immobilized substrate we
could detect the presence of fluoropyruvate at lower
concentrations than those required when using immobilized G3P, probably because of the requirement in
the latter case of soluble pyruvate in solution, that will
compete with the inhibitor for DXS binding (41). This,
in addition to the tedious synthesis of the G3P derivative
when compared with commercially available mercaptopyruvate, makes a pyruvate-based sensor the preferred configuration. The higher efficiency of fluoropyruvate relative to
pyruvate in preventing DXS binding to its immobilized
substrate likely reflects an increased residence time or
the induction of conformational changes in the active
center that might be related to the molecular mechanism of inhibition. This opens good perspectives
regarding the application of SMFS-based nanosensors to the biodiscovery of novel enzyme inhibitors
found in minute amounts. Enzymatic assays have
established fluoropyruvate as a DXS competitive inhibitor with a Ki of 1 mM (41), whereas we have
shown that an SMFS-based nanosensor can detect 10
M fluoropyruvate by using conventional experimental protocols and commercial AFM cantilevers. Considering that fluoropyruvate is a relatively weak DXS
inhibitor, more active compounds (78) can presumably be discovered at concentrations within the nanomolar range using the SMFS approach presented
here. We foresee that maximal resolution can be
attained when nanofabrication methods will permit
the functionalization of force nanosensors carrying a
single enzyme molecule (Fig. 9B, C). Such future
truly single-molecule devices will open the field for
the coupling to very small scale synthesis of combinatorial chemical libraries and for the biodiscovery
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Palumbi, S. R. (2001) Humans as the world’s greatest evolutionary force. Science 293, 1786 –1790
Walsh, C. (2003) Where will new antibiotics come from? Nat.
Rev. Microbiol. 1, 65–70
Beytia, E. D., and Porter, J. W. (1976) Biochemistry of polyisoprenoid biosynthesis. Annu. Rev. Biochem. 45, 113–142
Eisenreich, W., Rohdich, F., and Bacher, A. (2001) Deoxyxylulose phosphate pathway to terpenoids. Trends Plant Sci. 6, 78 – 84
Takahashi, S., Kuzuyama, T., Watanabe, H., and Seto, H. (1998)
A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing
the formation of 2-C-methyl-D-erythritol 4-phosphate in an
alternative nonmevalonate pathway for terpenoid biosynthesis.
Proc. Natl. Acad. Sci. U. S. A. 95, 9879 –9884
Rohdich, F., Kis, K., Bacher, A., and Eisenreich, W. (2001) The
non-mevalonate pathway of isoprenoids: genes, enzymes and
intermediates. Curr. Opin. Chem. Biol. 5, 535–540
Rodríguez-Concepción, M. (2004) The MEP pathway: a new
target for the development of herbicides, antibiotics and antimalarial drugs. Curr. Pharm. Des. 10, 2391–2400
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Turbachova, I., Eberl, M., Zeidler, J.,
Lichtenthaler, H. K., Soldati, D., and Beck, E. (1999) Inhibitors
of the nonmevalonate pathway of isoprenoid biosynthesis as
antimalarial drugs. Science 285, 1573–1576
Ralph, S. A., D’Ombrain, M. C., and McFadden, G. I. (2001)
The apicoplast as an antimalarial drug target. Drug Resist. Updat.
4, 145–151
Jain, K. K. (2005) The role of nanobiotechnology in drug
discovery. Drug Discov. Today 10, 1435–1442
Santos-Magalhaes, N. S., and Mosqueira, V. C. (2010) Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev.
62, 560 –575
Bizzarri, A. R., and Cannistraro, S. (2010) The application of
atomic force spectroscopy to the study of biological complexes
undergoing a biorecognition process. Chem. Soc. Rev. 39, 734 –
749
Bustamante, C., Macosko, J. C., and Wuite, G. J. (2000) Grabbing the cat by the tail: manipulating molecules one by one. Nat.
Rev. Mol. Cell. Biol. 1, 130 –136
Evans, E., and Ritchie, K. (1997) Dynamic strength of molecular
adhesion bonds. Biophys. J. 72, 1541–1555
Merkel, R., Nassoy, P., Leung, A., Ritchie, K., and Evans, E.
(1999) Energy landscapes of receptor-ligand bonds explored
with dynamic force spectroscopy. Nature 397, 50 –53
Zlatanova, J., Lindsay, S. M., and Leuba, S. H. (2000) Single
molecule force spectroscopy in biology using the atomic force
microscope. Prog. Biophys. Mol. Biol. 74, 37– 61
Perez-Jimenez, R., Li, J., Kosuri, P., Sanchez-Romero, I., Wiita,
A. P., Rodriguez-Larrea, D., Chueca, A., Holmgren, A., MirandaVizuete, A., Becker, K., Cho, S. H., Beckwith, J., Gelhaye, E.,
Jacquot, J. P., Gaucher, E. A., Sanchez-Ruiz, J. M., Berne, B. J.,
and Fernandez, J. M. (2009) Diversity of chemical mechanisms
in thioredoxin catalysis revealed by single-molecule force spectroscopy. Nat. Struct. Mol. Biol. 16, 890 – 896
Sletmoen, M., Skjak-Braek, G., and Stokke, B. T. (2005) Mapping enzymatic functionalities of mannuronan C-5 epimerases
and their modular units by dynamic force spectroscopy. Carbohydr. Res. 340, 2782–2795
4215
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
4216
Wiita, A. P., Perez-Jimenez, R., Walther, K. A., Gräter, F., Berne,
B. J., Holmgren, A., Sanchez-Ruiz, J. M., and Fernandez, J. M.
(2007) Probing the chemistry of thioredoxin catalysis with force.
Nature 450, 124 –127
Yingge, Z., Chunli, B., Chen, W., and Delu, Z. (2001) Force
spectroscopy between acetylcholine and single acetylcholinesterase molecules and the effects of inhibitors and reactivators
studied by atomic force microscopy. J. Pharmacol. Exp. Ther. 297,
798 – 803
Fiorini, M., McKendry, R., Cooper, M. A., Rayment, T., and
Abell, C. (2001) Chemical force microscopy with active enzymes. Biophys. J. 80, 2471–2476
Kamper, S. G., Porter-Peden, L., Blankespoor, R., Sinniah, K.,
Zhou, D., Abell, C., and Rayment, T. (2007) Investigating the
specific interactions between carbonic anhydrase and a sulfonamide inhibitor by single-molecule force spectroscopy. Langmuir 23, 12561–12565
Porter-Peden, L., Kamper, S. G., Wal, M. V., Blankespoor, R.,
and Sinniah, K. (2008) Estimating kinetic and thermodynamic
parameters from single molecule enzyme-inhibitor interactions.
Langmuir 24, 11556 –11561
Maki, T., Kidoaki, S., Usui, K., Suzuki, H., Ito, M., Ito, F.,
Hayashizaki, Y., and Matsuda, T. (2007) Dynamic force spectroscopy of the specific interaction between the PDZ domain and its
recognition peptides. Langmuir 23, 2668 –2673
Evans, E., Leung, A., Heinrich, V., and Zhu, C. (2004) Mechanical switching and coupling between two dissociation pathways
in a P-selectin adhesion bond. Proc. Natl. Acad. Sci. U. S. A. 101,
11281–11286
Funari, G., Domenici, F., Nardinocchi, L., Puca, R., D’Orazi, G.,
Bizzarri, A. R., and Cannistraro, S. (2010) Interaction of p53
with Mdm2 and azurin as studied by atomic force spectroscopy.
J. Mol. Recog. 23, 343–351
Taranta, M., Bizzarri, A. R., and Cannistraro, S. (2008) Probing
the interaction between p53 and the bacterial protein azurin by
single molecule force spectroscopy. J. Mol. Recognit. 21, 63–70
Rico, F., and Moy, V. T. (2007) Energy landscape roughness of
the streptavidin-biotin interaction. J. Mol. Recognit. 20, 495–501
Neuert, G., Albrecht, C., Pamir, E., and Gaub, H. E. (2006)
Dynamic force spectroscopy of the digoxigenin-antibody complex. FEBS Lett. 580, 505–509
Allen, S., Chen, X., Davies, J., Davies, M. C., Dawkes, A. C.,
Edwards, J. C., Roberts, C. J., Sefton, J., Tendler, S. J., and
Williams, P. M. (1997) Detection of antigen-antibody binding
events with the atomic force microscope. Biochemistry 36, 7457–
7463
Schwesinger, F., Ros, R., Strunz, T., Anselmetti, D., Güntherodt,
H. J., Honegger, A., Jermutus, L., Tiefenauer, L., and Pluckthun, A. (2000) Unbinding forces of single antibody-antigen
complexes correlate with their thermal dissociation rates. Proc.
Natl. Acad. Sci. U. S. A. 97, 9972–9977
Hinterdorfer, P., Baumgartner, W., Gruber, H. J., Schilcher, K.,
and Schindler, H. (1996) Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Proc. Natl. Acad. Sci. U. S. A. 93, 3477–3481
Bartels, F. W., Baumgarth, B., Anselmetti, D., Ros, R., and
Becker, A. (2003) Specific binding of the regulatory protein
ExpG to promoter regions of the galactoglucan biosynthesis
gene cluster of Sinorhizobium meliloti—a combined molecular
biology and force spectroscopy investigation. J. Struct. Biol. 143,
145–152
Kühner, F., Costa, L. T., Bisch, P. M., Thalhammer, S., Heckl,
W. M., and Gaub, H. E. (2004) LexA-DNA bond strength by
single molecule force spectroscopy. Biophys. J. 87, 2683–2690
Bonanni, B., Bizzarri, A. R., and Cannistraro, S. (2006) Optimized biorecognition of cytochrome c 551 and azurin immobilized on thiol-terminated monolayers assembled on Au(111)
substrates. J. Phys. Chem. B 110, 14574 –14580
Garcia-Manyes, S., Bucior, I., Ros, R., Anselmetti, D., Sanz, F.,
Burger, M. M., and Fernàndez-Busquets, X. (2006) Proteoglycan
mechanics studied by single-molecule force spectroscopy of
allotypic cell adhesion glycans. J. Biol. Chem. 281, 5992–5999
Anselmetti, D., Fritz, J., Smith, B., and Fernàndez-Busquets, X.
(2000) Single molecule DNA biophysics with atomic force
microscopy. Single Mol. 1, 53–58
Meadows, P. Y., Bemis, J. E., and Walker, G. C. (2003) Singlemolecule force spectroscopy of isolated and aggregated fi-
Vol. 24
November 2010
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
bronectin proteins on negatively charged surfaces in aqueous
liquids. Langmuir 19, 9566 –9572
Rief, M., and Grubmüller, H. (2002) Force spectroscopy of
single biomolecules. Chemphyschem 3, 255–261
Green, J. B. D., Novoradovsky, A., Park, D., and Lee, G. U.
(1999) Microfabricated tip arrays for improving force measurements. Appl. Phys. Lett. 74, 1489 –1491
Eubanks, L. M., and Poulter, C. D. (2003) Rhodobacter
capsulatus 1-deoxy-D-xylulose 5-phosphate synthase: steadystate kinetics and substrate binding. Biochemistry 42, 1140 –
1149
Hibbert, H., and Whelen, M. S. (1929) Studies on reactions
relating to carbohydrates and polysaccharides. XXIII. Synthesis
and properties of hydroxy alkylidene glycols and glycerols.
J. Am. Chem. Soc. 51, 3115–3123
Wilkinson, T. A., Yin, J., Pidgeon, C., and Post, C. B. (2000)
Alkylation of cysteine-containing peptides to mimic palmitoylation. J. Peptide. Res. 55, 140 –147
Querol, J., Rodríguez-Concepción, M., Boronat, A., and Imperial, S. (2001) Essential role of residue H49 for activity of
Escherichia coli 1-deoxy-D-xylulose 5-phosphate synthase, the enzyme catalyzing the first step of the 2-C-methyl-D-erythritol
4-phosphate pathway for isoprenoid synthesis. Biochem. Biophys.
Res. Commun. 289, 155–160
Bradford, M. M. (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal. Biochem. 72, 248 –254
Lyubchenko, Y., Shlyakhtenko, L., Harrington, R., Oden, P.,
and Lindsay, S. (1993) Atomic force microscopy of long DNA:
imaging in air and under water. Proc. Natl. Acad. Sci. U. S. A. 90,
2137–2140
Hegner, M., Wagner, P., and Semenza, G. (1993) Ultralarge
atomically flat template-stripped Au surfaces for scanning probe
microscopy. Surf. Sci. 291, 39 – 46
Frey, B. L., and Corn, R. M. (1996) Covalent attachment and
derivatization of poly(L-lysine) monolayers on gold surfaces as
characterized by polarization-modulation FT-IR spectroscopy.
Anal. Chem. 68, 3187–3193
Altincicek, B., Hintz, M., Sanderbrand, S., Wiesner, J., Beck, E.,
and Jomaa, H. (2000) Tools for discovery of inhibitors of the
1-deoxy-D-xylulose 5-phosphate (DXP) synthase and DXP reductoisomerase: an approach with enzymes from the pathogenic bacterium Pseudomonas aeruginosa. FEMS Microbiol. Lett.
190, 329 –333
Hoeffler, J. F., Tritsch, D., Grosdemange-Billiard, C., and
Rohmer, M. (2002) Isoprenoid biosynthesis via the methylerythritol phosphate pathway. Mechanistic investigations of the 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Eur. J. Biochem.
269, 4446 – 4457
Lois, L. M., Campos, N., Putra, S. R., Danielsen, K., Rohmer, M.,
and Boronat, A. (1998) Cloning and characterization of a gene
from Escherichia coli encoding a transketolase-like enzyme that
catalyzes the synthesis of D-1-deoxyxylulose 5-phosphate, a common precursor for isoprenoid, thiamin, and pyridoxol biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 95, 2105–2110
Florin, E. L., Rief, M., Lehmann, H., Ludwig, M., Dornmair, C.,
Moy, V. T., and Gaub, H. E. (1995) Sensing specific molecular
interactions with the atomic force microscope. Biosens. Bioelectron. 10, 895–901
Eckel, R., Wilking, S. D., Becker, A., Sewald, N., Ros, R., and
Anselmetti, D. (2005) Single-molecule experiments in synthetic
biology: an approach to the affinity ranking of DNA-binding
peptides. Angew. Chem. Int. Ed. Engl. 44, 3921–3924
Xiang, S., Usunow, G., Lange, G., Busch, M., and Tong, L.
(2007) Crystal structure of 1-deoxy-D-xylulose 5-phosphate synthase, a crucial enzyme for isoprenoids biosynthesis. J. Biol.
Chem. 282, 2676 –2682
Schürmann, M., Schürmann, M., and Sprenger, G. A. (2002)
Fructose 6-phosphate aldolase and 1-deoxy-D-xylulose 5-phosphate synthase from Escherichia coli as tools in enzymatic synthesis of 1-deoxysugars. J. Mol. Catal. B 19 –20, 247–252
Sodhi, R. N. (2004) Time-of-flight secondary ion mass spectrometry (TOF-SIMS): versatility in chemical and imaging surface
analysis. Analyst 129, 483– 487
Myszka, D. G. (1997) Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr. Opin.
Biotechnol. 8, 50 –57
The FASEB Journal 䡠 www.fasebj.org
SISQUELLA ET AL.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Schürmann, M. (2001) 1-Deoxy-D-xylulose-5-phosphat Synthase von
Escherichia coli: biochemische Charakterisierung und Struktur-Funktionsbeziehungen. Ph.D. thesis, Universität Düsseldorf
Kraut, D. A., Carroll, K. S., and Herschlag, D. (2003) Challenges in
enzyme mechanism and energetics. Annu. Rev. Biochem. 72, 517–571
Vane, J. R., and Botting, R. M. (1998) Anti-inflammatory drugs
and their mechanism of action. Inflamm. Res. 47(Suppl. 2),
S78 –S87
Menard, J., and Patchett, A. A. (2001) Angiotensin-converting
enzyme inhibitors. Adv. Protein Chem. 56, 13–75
Prendergast, G. C., and Oliff, A. (2000) Farnesyltransferase
inhibitors: antineoplastic properties, mechanisms of action, and
clinical prospects. Semin. Cancer Biol. 10, 443– 452
Kaubisch, A., and Schwartz, G. K. (2000) Cyclin-dependent
kinase and protein kinase C inhibitors: a novel class of
antineoplastic agents in clinical development. Cancer J. 6,
192–212
Mathijssen, R. H., Loos, W. J., Verweij, J., and Sparreboom, A.
(2002) Pharmacology of topoisomerase I inhibitors irinotecan
(CPT-11) and topotecan. Curr. Cancer Drug Targets 2, 103–123
Simpson, E. R., and Dowsett, M. (2002) Aromatase and its
inhibitors: significance for breast cancer therapy. Recent. Prog.
Horm. Res. 57, 317–338
Finberg, J. P. (1995) Pharmacology of reversible and selective
inhibitors of monoamine oxidase type A. Acta Psychiatr. Scand.
Suppl. 386, 8 –13
Schmidt, D., Dent, G., and Rabe, K. F. (1999) Selective phosphodiesterase inhibitors for the treatment of bronchial asthma
and chronic obstructive pulmonary disease. Clin. Exp. Allergy
29(Suppl. 2), 99 –109
Olanow, C. W. (1993) MAO-B inhibitors in Parkinson’s disease.
Adv. Neurol. 60, 666 – 671
Thomas, T. (2000) Monoamine oxidase-B inhibitors in the
treatment of Alzheimer’s disease. Neurobiol. Aging 21, 343–348
INDIVIDUAL ENZYME HANDLING FOR DRUG DISCOVERY
70.
71.
72.
73.
74.
75.
76.
77.
78.
Frisoni, G. B. (2001) Treatment of Alzheimer’s disease with
acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J. Neurol. 248, 551–557
Ghosh, A. K., Hong, L., and Tang, J. (2002) -secretase as a
therapeutic target for inhibitor drugs. Curr. Med. Chem. 9,
1135–1144
Moghadasian, M. H. (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci.
65, 1329 –1337
Lebon, F., and Ledecq, M. (2000) Approaches to the design of
effective HIV-1 protease inhibitors. Curr. Med. Chem. 7, 455– 477
Nair, V. (2002) HIV integrase as a target for antiviral chemotherapy. Rev. Med. Virol. 12, 179 –193
Sauret-Güeto, S., Urós, E. M., Ibáñez, E., Boronat, A., and
Rodríguez-Concepción, M. (2006) A mutant pyruvate dehydrogenase E1 subunit allows survival of Escherichia coli strains
defective in 1-deoxy-D-xylulose 5-phosphate synthase. FEBS
Lett. 580, 736 –740
Wiesner, J., Borrmann, S., and Jomaa, H. (2003) Fosmidomycin for
the treatment of malaria. Parasitol. Res. 90(Suppl. 2), S71–S76
Borrmann, S., Lundgren, I., Oyakhirome, S., Impouma, B.,
Matsiegui, P. B., Adegnika, A. A., Issifou, S., Kun, J. F. J.,
Hutchinson, D., Wiesner, J., Jomaa, H., and Kremsner, P. G.
(2006) Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum
malaria. Antimicrob. Agents Chemother. 50, 2713–2718
Mao, J., Eoh, H., He, R., Wang, Y., Wan, B., Franzblau, S. G.,
Crick, D. C., and Kozikowski, A. P. (2008) Structure-activity
relationships of compounds targeting Mycobacterium tuberculosis
1-deoxy-D-xylulose 5-phosphate synthase. Bioorg. Med. Chem. Lett.
18, 5320 –5323
Received for publication February 11, 2010.
Accepted for publication June 24, 2010.
4217